Quick Answer
Menstrual changes are not listed as a common side effect in the FDA prescribing information for semaglutide (the active ingredient in Wegovy and Ozempic), and semaglutide is not known to act directly on the ovaries or the uterus. Even so, many women notice their cycle shifting during treatment, and there is a well-documented reason: meaningful weight loss changes your hormonal environment. Body weight influences the hormone signals that time ovulation, so meaningful weight change can make periods earlier, later, lighter, heavier, or more regular than before.
The honest summary of the science: direct evidence on semaglutide and the menstrual cycle is limited, because the major clinical trials were not designed to track cycle changes. What is well established is the relationship between weight change and the cycle, and two practical safety points from FDA labeling that every woman on semaglutide should know: the birth control guidance and the 2-month rule before a planned pregnancy. This guide covers all of it. Semaglutide is a prescription medication, prescribed only if a licensed physician determines it is appropriate for you.
What FDA Labeling and Clinical Trials Say
Start with what the official sources actually contain.
- FDA prescribing information for Wegovy and Ozempic lists gastrointestinal effects (nausea, vomiting, diarrhea, constipation) as the most common adverse reactions. Menstrual irregularity does not appear on those lists.
- The clinical trial data summarized in FDA labeling show the same side effect profile dominated by gastrointestinal events, and menstrual changes are not reported there.
- Published research specifically on semaglutide and menstruation is sparse. There is no large controlled study isolating the medication's effect on the cycle from the effect of the weight loss it produces.
So when women report period changes on semaglutide, and many do, the most evidence-supported explanation is not a direct drug effect. It is the body responding to a changing weight, which is a real and sometimes noticeable hormonal event. That distinction matters, because it tells you what to watch and when a symptom deserves medical attention rather than reassurance.
Why Cycles Change Anyway: Weight Loss and Your Hormones
Your menstrual cycle is regulated by a hormonal conversation between the brain (hypothalamus and pituitary) and the ovaries. Body fat participates in that conversation more than most people realize.
- Body fat is part of the conversation. Body fat takes part in the hormone signals that time ovulation, and absent periods are more common in women with obesity, as the NIH's MedlinePlus notes.
- Losing fat rebalances the signal. As weight comes down, those hormone signals shift, and MedlinePlus notes that a lack of periods linked to obesity may respond to weight control. For some women that restores more regular ovulation. For others, the transition period shows up as temporarily unpredictable cycle timing or flow while the system recalibrates.
- Appetite and stress hormones shift too. Semaglutide changes how much you eat, and large changes in energy intake feed into the same brain centers that regulate reproduction.
The practical takeaway: a cycle that shifts modestly during active weight loss is common and usually reflects the weight change, not medication toxicity. Track your cycle in an app or calendar from the day you start treatment, so you and your physician can see the pattern rather than guessing.
Missed Periods: Rapid Weight Loss and Under-Eating
There is one cycle change that deserves specific attention: periods that stop. Two explanations are far more likely than a direct medication effect, and both are checkable.
First, pregnancy. It sounds paradoxical, but weight loss can restore ovulation in women who were not ovulating regularly before, which means fertility can return without warning. Any missed period on semaglutide should start with a pregnancy test. More on this below.
Second, under-eating. When the body senses a sustained energy deficit, it can downshift reproduction to conserve resources. The result is suppressed ovulation and missed periods, a condition called functional hypothalamic amenorrhea, described in the Endocrine Society's 2017 clinical practice guideline. Because semaglutide is powerful at reducing appetite, some patients drift into eating very little without noticing, especially during dose escalation. Alongside missed periods, warning signs include fatigue, hair shedding, feeling cold, and losing more than the gradual pace your physician expects. Shedding has its own explanation and its own timeline, set out in semaglutide and hair loss.
If that picture sounds familiar, do not push through it. Talk to your prescriber about your eating pattern and dose, and review our guide on what to eat on semaglutide for how to cover protein and overall nutrition when your appetite is quiet.
PCOS: When Cycles May Become More Regular
For women with polycystic ovary syndrome, the story can run in the opposite direction: weight management is linked to clinical improvements, although whether GLP-1 medications themselves improve cycles is still a research question.
PCOS commonly involves insulin resistance, and excess insulin drives the androgen excess that disrupts ovulation. Weight reduction improves insulin sensitivity, and the 2023 International Evidence-based Guideline for PCOS makes lifestyle management a core focus of care, noting that in women with higher weight, weight management can be associated with significant clinical improvements. The same guideline says GLP-1 medications could be considered, alongside lifestyle intervention, for managing higher weight in adults with PCOS, while recommending their use for reproductive outcomes only in research settings, and PCOS is not an FDA-approved indication for semaglutide.
Two honest caveats. These improvements flow mainly from improved metabolic health, not from a direct ovarian effect of the drug. And more regular ovulation means higher fertility, which brings us to the next section. If PCOS is your reason for reading this, our guide to PCOS belly and the insulin picture behind it covers that mechanism in depth.
Ovulation and Fertility: The Surprise-Pregnancy Question
News coverage has popularized the phrase "Ozempic babies": unplanned pregnancies in women taking GLP-1 medications, some of whom believed they could not conceive. There is no evidence that semaglutide is a fertility drug. The plausible mechanism is simpler: weight loss restored ovulation in women whose cycles had been suppressed, and contraception either was not being used or, in some cases involving other GLP-1 medications, may have been less reliable (see the birth control section below).
If you are a woman of reproductive age starting semaglutide, treat returning fertility as a real possibility rather than a curiosity:
- Use reliable contraception if you are not planning a pregnancy, even if your periods have been irregular or absent for years.
- Take a pregnancy test for any missed period.
- Tell your prescriber immediately if you become pregnant. Wegovy's FDA labeling says to discontinue treatment when pregnancy is recognized, and there is a pregnancy exposure registry for Wegovy that collects safety data.
Does Semaglutide Affect Birth Control?
This is one of the most searched questions in this topic, and the answer differs by medication, so precision matters.
Semaglutide: the medication slows stomach emptying, which raises a fair question about whether pills absorb properly. FDA labeling for semaglutide addresses it directly: in clinical pharmacology trials, semaglutide did not affect the absorption of orally administered medications to any clinically relevant degree, and the labeling reports no clinically significant differences in the pharmacokinetics of ethinyl estradiol or levonorgestrel when taken with semaglutide. The labeling gives no backup-method instruction for semaglutide, though it does say caution should be exercised when oral medications are taken alongside it.
Tirzepatide (Zepbound, Mounjaro) is different. Its FDA labeling advises patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation, because tirzepatide may reduce oral contraceptive exposure. If you are comparing the two medications, this is one of the practical differences; see our full tirzepatide vs semaglutide comparison.
One common-sense addition that applies to any GLP-1 medication: oral contraceptives rely on keeping the pill down. If nausea and vomiting are frequent during your dose escalation, ask your prescriber whether a backup method is sensible until your stomach settles. Managing those GI effects is covered in our GLP-1 side effects guide.
Planning a Pregnancy: Stop at Least 2 Months Before
FDA labeling for semaglutide is unambiguous here: discontinue semaglutide at least 2 months before a planned pregnancy. The reason is pharmacokinetic. Semaglutide has a long half-life, so it stays in the body for weeks after the last dose, and animal studies reported fetal risk, so labeling recommends clearing the medication before conception. Weight loss itself offers no benefit during pregnancy and may cause fetal harm, per the same labeling.
Practical sequence if a pregnancy is on your horizon:
- Tell your prescriber you are planning to conceive. Timing the stop is a medical decision made with your physician, not a solo one.
- Build the off-ramp plan: appetite typically returns after stopping, so agree on nutrition and weight-maintenance strategy for the washout window and pregnancy itself.
- Keep contraception in place until the agreed stop-and-clear plan actually starts.
Perimenopause: Is It the Medication or the Transition?
Women in their 40s and early 50s face a genuinely confusing overlap. Perimenopause itself makes cycles irregular, heavier, lighter, or skipped, and it is also a common age to start a GLP-1 medication for weight that has become harder to manage. When the cycle changes, which cause is it?
There is no home test that separates the two, and that is exactly why this deserves a physician conversation instead of guesswork. A clinician can consider your age, cycle history, symptoms like hot flashes or sleep disruption, and, when useful, lab work. Two things are worth knowing. First, cycle changes from weight loss and cycle changes from perimenopause can happen at the same time. Second, any bleeding after 12 months without a period (postmenopausal bleeding) is never attributed to a weight loss medication: it requires prompt medical evaluation, full stop.
For how GLP-1 treatment fits the menopause transition more broadly, including hormone therapy questions, see our guide to semaglutide and menopause weight gain.
When to Call Your Doctor
Most cycle shifts during gradual weight loss are benign. These are not, and they warrant contacting a clinician promptly rather than waiting:
- A missed period (take a pregnancy test first, then call)
- Very heavy bleeding: soaking through a pad or tampon every hour for several hours, or passing large clots
- Bleeding between periods, or bleeding after sex
- Any bleeding after menopause
- Periods that stop for 3 months or more without pregnancy
- Severe pelvic pain
- Signs of under-eating alongside cycle changes: pronounced fatigue, hair shedding, feeling cold, rapid ongoing weight loss
None of these should be self-diagnosed as "just the semaglutide." Each has a standard medical workup, and cycle changes are always worth reporting to your prescriber at your next check-in even when mild.
The Bottom Line
Semaglutide is not documented to act directly on the menstrual cycle, and menstrual changes are not in its FDA-listed side effects. But the weight loss it produces is a genuine hormonal event, and cycles often respond: sometimes more regular, sometimes temporarily unpredictable, sometimes paused when eating falls too low. The evidence specific to semaglutide is limited, so honest tracking beats assumption: log your cycle, use reliable contraception if pregnancy is not the plan, remember the 2-month rule if it is, and bring any significant change to a licensed physician. Semaglutide is prescribed only if a licensed physician determines it is appropriate, and the same physician relationship is where cycle questions belong.
For the broader picture of what to expect on treatment, start with our compounded semaglutide guide and the GLP-1 side effects guide.
*Related guides:*
- GLP-1 side effects: what to expect and how to manage them
- What to eat on semaglutide
- PCOS belly: why it happens and what helps
- Semaglutide for menopause weight gain
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about your menstrual cycle, contraception, or pregnancy planning. Statements about medication effects reference FDA prescribing information for Wegovy, Ozempic, Zepbound, and Mounjaro and published clinical literature as of September 2026. Compounded medications are not FDA-approved as final products. Individual results may vary.
Frequently Asked Questions
Does semaglutide affect your period?
Menstrual changes are not listed as a common side effect in the FDA prescribing information for semaglutide (Wegovy, Ozempic), and the medication is not known to act directly on the ovaries or uterus. Most cycle changes reported during treatment are linked to weight loss itself, which shifts the hormone signals that time ovulation. Published evidence on semaglutide and the menstrual cycle is limited, so track your cycle and tell your physician about significant changes.
Can semaglutide cause a missed period?
Not directly, as far as current evidence shows. Losing weight quickly or eating too little can suppress ovulation and pause periods, a pattern known as functional hypothalamic amenorrhea. Rule out pregnancy first: weight loss can restore ovulation, so take a pregnancy test for any missed period and tell your physician.
Can semaglutide make your period irregular or heavier?
Some women report irregular, lighter, or heavier periods while taking semaglutide, but these reports are anecdotal and published data is limited. Meaningful weight change shifts the hormone signals that time ovulation, which can change cycle length and flow in either direction. See a doctor promptly for very heavy bleeding, bleeding between periods, or any bleeding after menopause.
Does semaglutide affect birth control pills?
Per FDA labeling, semaglutide did not affect the absorption of orally administered medications to a clinically relevant degree, with no clinically significant differences in the pharmacokinetics of ethinyl estradiol or levonorgestrel, and the labeling gives no backup-method instruction for semaglutide specifically. Tirzepatide (Zepbound, Mounjaro) is different: its labeling advises a barrier or non-oral method for 4 weeks after starting and after each dose increase. If you vomit frequently on either medication, ask your prescriber whether a backup method makes sense.
Can semaglutide increase fertility?
Indirectly, yes. Weight loss can restore ovulation in women whose cycles were suppressed by weight-related hormonal changes or PCOS-related insulin resistance, which raises the chance of pregnancy, sometimes unexpectedly. Semaglutide is not a fertility treatment, and reliable contraception matters if you are not planning a pregnancy.
Do I need to stop semaglutide before getting pregnant?
Yes. FDA labeling recommends discontinuing semaglutide at least 2 months before a planned pregnancy, because the medication clears from the body slowly. Make that change with your physician, not on your own.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.WEGOVY (SEMAGLUTIDE) INJECTION, SOLUTION; WEGOVY (SEMAGLUTIDE) TABLET [NOVO NORDISK PHARMACEUTICAL INDUSTRIES, LP], sections Adverse Reactions (Highlights), 8.1 Pregnancy, 8.3 Females and Males of Reproductive Potential, and 12.3 Pharmacokinetics · DailyMed, U.S. National Library of Medicine (FDA-submitted prescribing information, revised 6/2026) · accessed
- 2.OZEMPIC (SEMAGLUTIDE) INJECTION, SOLUTION [NOVO NORDISK PHARMACEUTICAL INDUSTRIES, LP], section 7.2 Oral Medications · DailyMed, U.S. National Library of Medicine (FDA-submitted prescribing information, revised 5/2026) · accessed
- 3.ZEPBOUND (TIRZEPATIDE) INJECTION, SOLUTION; ZEPBOUND KWIKPEN [ELI LILLY AND COMPANY], section 8.3 Females and Males of Reproductive Potential (Highlights) · DailyMed, U.S. National Library of Medicine (FDA-submitted prescribing information, revised 8/2026) · accessed
- 4.Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(5):1413-1439. PMID 28368518 · PubMed, U.S. National Library of Medicine (Endocrine Society guideline) · accessed
- 5.Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38(9):1655-1679. PMC10477934, recommendations 3.1.3, 3.1.6, 4.5.1 and 5.9.1 · PubMed Central, U.S. National Library of Medicine · accessed
- 6.Absent menstrual periods - secondary: MedlinePlus Medical Encyclopedia · MedlinePlus, U.S. National Library of Medicine · accessed
- 7.21 U.S. Code § 353a - Pharmacy compounding · Legal Information Institute, Cornell Law School (United States Code) · accessed
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them
